Trial Profile

Multicenter PK PD Study of Immune Checkpoint Inhibitors for Patients Aged 75 or Older with Advanced Non Small Cell Lung Cancer.

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 13 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary)
Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
Focus Pharmacokinetics
Acronyms Elderly Pembro trial

Most Recent Events

24 Oct 2023 Results assessing the efficacy, safety and pharmacokinetics of pembrolizumab for non-small cell lung cancer in elderly adults aged over 75 years, presented at the 48th European Society for Medical Oncology Congress.
06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
19 Apr 2023 Results presented at the 114th Annual Meeting of the American Association for Cancer Research

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com